Crossmark

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

Crossref DOI link: https://doi.org/10.1016/S1473-3099(17)30235-9

Published Print: 2017-07

Update policy: https://doi.org/10.1016/ELSEVIER_CM_POLICY

Authors

Vickers, Richard J

Tillotson, Glenn S

Nathan, Richard

Hazan, Sabine

Pullman, John

Lucasti, Christopher

Deck, Kenneth

Yacyshyn, Bruce

Maliakkal, Benedict

Pesant, Yves

Tejura, Bina

Roblin, David

Gerding, Dale N

Wilcox, Mark H

Bhan, Amit

Campbell, Wayne

Chopra, Teena

Deck, Kenneth

Golan, Yoav

Gordon, Ian

Kamepalli, Ravi

Khanna, Sahil

Lee, Christine

Lucasti, Christopher

Maliakkal, Benedict

Minang, Irene

Mullane, Kathleen

Nathan, Richard

Oughton, Matthew

Pesant, Yves

Phillips, John

Pullman, John

Riska, Paul

Schrock, Christian

Siegel, Jonathan

Steinberg, Alon

Talan, David

Tamang, Stephen

Tan, Michael

Weiss, Karl

Wang, Chia

Yacyshyn, Bruce

Young, Jo-Anne

Zenilman, Jonathan
License Information

Text and Data Mining valid from 2017-07-01

Version of Record valid from 2017-04-27
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

Journal Title: The Lancet Infectious Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1473-3099(17)30235-9

CrossRef DOI link to the associated document: https://doi.org/10.1016/S1473-3099(17)30237-2

Content Type: article

Copyright: © 2017 The Author(s). Published by Elsevier Ltd.

Document is current

Any future updates will be listed below